Eventide Asset Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Eventide Asset Management’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-190,000	Closed	-$1.47M	–	136
2016 Q4	$1.47M	Hold	190,000	–	–	0.1%	101
2016 Q3	$2.17M	Hold	190,000	–	–	0.13%	96
2016 Q2	$2.34M	Hold	190,000	–	–	0.14%	96
2016 Q1	$1.92M	Hold	190,000	–	–	0.11%	105
2015 Q4	$4.28M	Buy	190,000 +43,100	+29%	+$883K	0.21%	93
2015 Q3	$2.44M	Buy	146,900 +61,800	+73%	+$1.24M	0.14%	94
2015 Q2	$1.92M	Hold	85,100	–	–	0.1%	98
2015 Q1	$2.19M	Buy	85,100 +32,300	+61%	+$819K	0.17%	92
2014 Q4	$1.15M	Hold	52,800	–	–	0.13%	95
2014 Q3	$1M	Hold	52,800	–	–	0.14%	92
2014 Q2	$1.23M	Hold	52,800	–	–	0.17%	93
2014 Q1	$1.78M	Buy	52,800 +30,300	+135%	+$1.02M	0.28%	74
2013 Q4	$664K	Buy	+22,500	New	+$412K	0.2%	72

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Eventide Asset Management's OMED Position: Q1 2017 in Review

Eventide Asset Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2017, closing a stake of 190,000 shares — an estimated $1.47M sold.

Eventide Asset Management first reported a position in OMED in Q4 2013 and held it in 13 quarters. The position peaked at $4.28M in Q4 2015. 85 funds tracked by Wall St. Rank hold OMED as of Q1 2017.

Eventide Asset Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Eventide Asset Management sold 190,000 OncoMed Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1.47M.
Eventide Asset Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2013 and held it in 13 quarters.
Eventide Asset Management's OncoMed Pharmaceuticals, Inc. position peaked at $4.28M in Q4 2015.
85 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2017.

Based on Eventide Asset Management's 13F filing for Q1 2017, filed 15 May 2017.